Sign inJoin waitlistJoin the waitlist

James Markert

Professor & Chair of Neurosurgery · University of Alabama Hospital

Credentials: · · · ·

History

Neurosurgery Department · University of Alabama Hospital
Present
Department of Neurosurgery · University of Alabama Hospital
Present
University of Alabama Hospital
Present

Massachusetts General Hospital
1998–1999
Neurological Surgery
University of Alabama Hospital
1991–1998
University of Michigan
1988–1991
Harvard University
Columbia Univ Coll of Phys & Surgeons
1984–1988
Harvard University
1980–1984

Research

Experimental therapy of human glioma by means of a genetically engineered virus mutant
Science · 1991 · 835 citations
Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial
Gene Therapy · 2000 · First of 11 authors · 808 citations
A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant…
Molecular Therapy · 2004 · 334 citations

John Fiveash
38 papers
Gregory Friedman
32 papers
Richard Whitley
29 papers
Louis Nabors
21 papers
Kevin Cassady
20 papers
Elizabeth Beierle
17 papers
Christopher Willey
16 papers
Kristen Riley
15 papers · 1 as a fellow
BG
Barton Guthrie
14 papers
Dagoberto Estévez
13 papers · 13 as a resident
JB
Joshua Bernstock
13 papers · 12 as a resident
Markus Bredel
12 papers · 1 as a resident

Grants

Imaging-Computational Framework for Guiding Treatment of HGG: An oHSV Clinical Trial
National Cancer Institute · R01
PI · $643.8K · University of Alabama at Birmingham
2026–2031
Utilization of Immuno-PET to Detect Response and Guide Novel oHSV-Based Therapy for Glioma
National Cancer Institute · R01
PI · $2.3M · University of Alabama at Birmingham
2023–2028
Oncolytic Immunotherapy Using Chimeric HSV C134: A Phase I Trial and Establishment of Response Indicators in Recurrent Glioma Patients
National Cancer Institute · R01
Contact PI · $1.7M · University of Alabama at Birmingham
2018–2024
A Phase 1 Study of M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma.
National Cancer Institute · R01
Contact PI · $1.6M · University of Alabama at Birmingham
2017–2023

Clinical trials

Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1)
Principal investigator · Terminated · Phase 1
University of Alabama at Birmingham
2024–2025
Study of Pembrolizumab and M032 (NSC 733972)
Principal investigator · Recruiting · Phase 1, Phase 2
University of Alabama at Birmingham
2022–2028
Trial of C134 in Patients With Recurrent GBM
Principal investigator · Completed · Phase 1
University of Alabama at Birmingham
2019–2025
Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma
Principal investigator · Active not recruiting · Phase 1
University of Alabama at Birmingham
2013–2027